A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD
fluticasone propionate/salmeterol
Pulmonary Disease, Chronic Obstructive
Phase 3
All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An Analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013